Literature DB >> 1984534

Effectiveness and tolerance of long-term malaria prophylaxis with mefloquine. Need for a better dosing regimen.

H O Lobel1, K W Bernard, S L Williams, A W Hightower, L C Patchen, C C Campbell.   

Abstract

To measure the effectiveness and tolerance of long-term malaria prophylaxis with mefloquine, the incidence of Plasmodium falciparum malaria and of adverse reactions was compared in Peace Corps volunteers in West Africa who took mefloquine every 2 weeks and in volunteers who took chloroquine phosphate weekly. Mefloquine was only 63% more effective than chloroquine; the monthly incidence of P falciparum infections was one case per 100 volunteers who took mefloquine and 2.7 cases per 100 volunteers who took chloroquine. Using daily proguanil (chloroguanide) hydrochloride in addition to chloroquine did not provide additional protection. All mefloquine prophylaxis failures occurred during the second week of the every-2-weeks dosing regimen in volunteers who had used mefloquine for more than 2 months. Blood concentrations of mefloquine were lower during the second week of the alternate-week regimen than during the first week, suggesting that blood levels are too low during the second week to suppress parasitemia. No serious adverse reactions were observed. The results indicate that a dosing regimen of 250 mg of mefloquine weekly should be considered for travelers to areas with chloroquine-resistant P falciparum malaria.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1984534

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  11 in total

1.  Clearing the air on malaria.

Authors:  R Wittes
Journal:  CMAJ       Date:  1991-03-15       Impact factor: 8.262

Review 2.  Halofantrine: a new substance for treatment of multidrug-resistant malaria.

Authors:  H D Nothdurft; R Clemens; H L Bock; T Löscher
Journal:  Clin Investig       Date:  1993-01

Review 3.  Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  K J Palmer; S M Holliday; R N Brogden
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

Review 4.  New antimalarials. A risk-benefit analysis.

Authors:  F Nosten; R N Price
Journal:  Drug Saf       Date:  1995-04       Impact factor: 5.606

Review 5.  Pharmacokinetic justification of antiprotozoal therapy. A US perspective.

Authors:  J D Berman; L Fleckenstein
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

Review 6.  Human antiprotozoal therapy: past, present, and future.

Authors:  M Khaw; C B Panosian
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

7.  Influence of hemodialysis on plasma concentration-time profiles of mefloquine in two patients with end-stage renal disease: a prophylactic drug monitoring study.

Authors:  C A Crevoisier; I Joseph; M Fischer; H Graf
Journal:  Antimicrob Agents Chemother       Date:  1995-08       Impact factor: 5.191

Review 8.  Mefloquine for preventing malaria during travel to endemic areas.

Authors:  Maya Tickell-Painter; Nicola Maayan; Rachel Saunders; Cheryl Pace; David Sinclair
Journal:  Cochrane Database Syst Rev       Date:  2017-10-30

9.  Summary of recommendations on malaria issues in special hosts.

Authors:  A Boggild; J Brophy; P Charlebois; M Crockett; J Geduld; W Ghesquiere; P McDonald; P Plourde; P Teitelbaum; M Tepper; S Schofield; A McCarthy
Journal:  Can Commun Dis Rep       Date:  2014-05-15

Review 10.  Malaria prophylaxis: taking aim at constantly moving targets.

Authors:  F J Bia
Journal:  Yale J Biol Med       Date:  1992 Jul-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.